Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2019

Open Access 01-12-2019 | Breast Cancer | Research

Mapping function from FACT-B to EQ-5D-5 L using multiple modelling approaches: data from breast cancer patients in China

Authors: Qing Yang, Xue Xin Yu, Wei Zhang, Hui Li

Published in: Health and Quality of Life Outcomes | Issue 1/2019

Login to get access

Abstract

Background

The Functional Assessment of Cancer Therapy-Breast (FACT-B) is the most commonly used scale for assessing quality of life in patients with breast cancer. The lack of preference-based measures limits the cost-utility of breast cancer in China. The goal of this study was to explore whether a mapping function can be established from the FACT-B to the EQ-5D-5 L when the EQ-5D health-utility index is not available.

Methods

A cross-sectional survey of adults with breast cancer was conducted in China. All patients included in the study completed the EQ-5D-5 L and the disease-specific FACT-B questionnaire, and demographic and clinical data were also collected. The Chinese tariff value was used to calculate the EQ-5D-5 L utility scores. Five models were evaluated using three different modelling approaches: the ordinary least squares (OLS) model, the Tobit model and the two-part model (TPM). Total scores, domain scores, squared terms and interaction terms were introduced into models. The goodness of fit, signs of the estimated coefficients, and normality of prediction errors of the model were also assessed. The normality of the prediction error is determined by calculating the root mean squared error (RMSE), the mean absolute deviation (MAD), and the mean absolute error (MAE). Akaike information criteria (AIC) and Bayes information criteria (BIC) were also used to assess models and predictive performances. The OLS model was followed by simple linear equating to avoid regression to the mean.

Results

The performance of the models was improved after the introduction of the squared terms and the interaction terms. The OLS model, including the squared terms and the interaction terms, performed best for mapping the EQ-5D-5 L. The explanatory power of the OLS model was 70.0%. The AIC and BIC of this model were the smallest (AIC = -705.106, BIC = -643.601). The RMSE, MAD and MAE of the OLS model, Tobit model and TPM were similar. The MAE values of the 5-fold cross-validation of the multiple models in this study were 0.07155~0.08509; meanwhile, the MAE of the TPM was the smallest, followed by that of the OLS model. The OLS regression proved to be the most accurate for the mean, and linearly equated scores were much closer to observed scores.

Conclusions

This study establishes a mapping algorithm based on the Chinese population to estimate the EQ-5D-5 L index of the FACT-B and confirms that OLS models have higher explanatory power and that TPMs have lower prediction error. Given the accuracy of the mean prediction and the simplicity of the model, we recommend using the OLS model. The algorithm can be used to calculate EQ-5D scores when EQ-5D data are not directly collected in a study.
Literature
1.
go back to reference Desantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62.PubMedCrossRef Desantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62.PubMedCrossRef
2.
go back to reference Chen WQ, Zheng RS. Incidence, mortality and survival analysis of breast cancer in China. Chin J Clin Oncol. 2015;42(13):668–74 Chinese. Chen WQ, Zheng RS. Incidence, mortality and survival analysis of breast cancer in China. Chin J Clin Oncol. 2015;42(13):668–74 Chinese.
3.
go back to reference Jones SM, LaCroix AZ, Li W, Zaslavsky O, Wassertheil-Smoller S, Weitlauf J, Brenes GA, Nassir R, Ockene JK, Caire-Juvera G, Danhauer SC. Depression and quality of life before and after breast cancer diagnosis in older women from the Women’s health initiative. J Cancer Surviv. 2015;9(4):620–9.PubMedPubMedCentralCrossRef Jones SM, LaCroix AZ, Li W, Zaslavsky O, Wassertheil-Smoller S, Weitlauf J, Brenes GA, Nassir R, Ockene JK, Caire-Juvera G, Danhauer SC. Depression and quality of life before and after breast cancer diagnosis in older women from the Women’s health initiative. J Cancer Surviv. 2015;9(4):620–9.PubMedPubMedCentralCrossRef
4.
go back to reference Karlsson KY, Wallenius I, Nilsson-Wikmar LB, Lindman H, Johansson BB. Lymphoedema and health-related quality of life by early treatment in long-term survivors of breast cancer. A comparative retrospective study up to 15 years after diagnosis. Support Care Cancer. 2015;23(10):2965–72.PubMedCrossRef Karlsson KY, Wallenius I, Nilsson-Wikmar LB, Lindman H, Johansson BB. Lymphoedema and health-related quality of life by early treatment in long-term survivors of breast cancer. A comparative retrospective study up to 15 years after diagnosis. Support Care Cancer. 2015;23(10):2965–72.PubMedCrossRef
5.
go back to reference Stover AM, Mayer DK, Muss H, Wheeler SB, Lyons JC, Reeve BB. Quality of life changes during the pre-to postdiagnosis period and treatment-related recovery time in older women with breast cancer. Cancer. 2014;120(12):1881–9.PubMedPubMedCentralCrossRef Stover AM, Mayer DK, Muss H, Wheeler SB, Lyons JC, Reeve BB. Quality of life changes during the pre-to postdiagnosis period and treatment-related recovery time in older women with breast cancer. Cancer. 2014;120(12):1881–9.PubMedPubMedCentralCrossRef
6.
go back to reference Wang L, Zhang Y, Shi JF, Dai M. Disease burden of famale breast cancer in China. Chinese J Epidemiol. 2016;37(7):970–6 Chinese. Wang L, Zhang Y, Shi JF, Dai M. Disease burden of famale breast cancer in China. Chinese J Epidemiol. 2016;37(7):970–6 Chinese.
7.
go back to reference Boyle FM, Smith IE, O’Shaughnessy J, Ejlertsen B, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Amonkar M, Huang Y, Rappold E, Williams LS, Wang-Silvanto J, Kaneko T, Finkelstein DM, Goss PE. Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. Eur J Cancer. 2015;51(6):685–96.PubMedCrossRef Boyle FM, Smith IE, O’Shaughnessy J, Ejlertsen B, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Amonkar M, Huang Y, Rappold E, Williams LS, Wang-Silvanto J, Kaneko T, Finkelstein DM, Goss PE. Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. Eur J Cancer. 2015;51(6):685–96.PubMedCrossRef
8.
go back to reference Cerezo O, Oñate-Ocaña LF, Arrieta-Joffe P, González-Lara F, García-Pasquel MJ, Bargalló-Rocha E, Vilar-Compte D. Validation of the Mexican-Spanish version of the EORTC QLQ-C30 and BR23 questionnaires to assess health-related quality of life in Mexican women with breast cancer. Eur J Cancer Care. 2012;21(5):684–91.CrossRef Cerezo O, Oñate-Ocaña LF, Arrieta-Joffe P, González-Lara F, García-Pasquel MJ, Bargalló-Rocha E, Vilar-Compte D. Validation of the Mexican-Spanish version of the EORTC QLQ-C30 and BR23 questionnaires to assess health-related quality of life in Mexican women with breast cancer. Eur J Cancer Care. 2012;21(5):684–91.CrossRef
9.
go back to reference Schleife H, Sachtleben C, Finck Barboza C, Singer S, Hinz A. Anxiety, depression, and quality of life in German ambulatory breast cancer patients. Breast Cancer. 2014;21(2):208–13.PubMedCrossRef Schleife H, Sachtleben C, Finck Barboza C, Singer S, Hinz A. Anxiety, depression, and quality of life in German ambulatory breast cancer patients. Breast Cancer. 2014;21(2):208–13.PubMedCrossRef
10.
go back to reference Maratia S, Cedillo S, Rejas J. Assessing health-related quality of life in patients with breast cancer: a systematic and standardized comparison of available instruments using the EMPRO tool. Qual Life Res. 2016;25(10):2467–80.PubMedCrossRef Maratia S, Cedillo S, Rejas J. Assessing health-related quality of life in patients with breast cancer: a systematic and standardized comparison of available instruments using the EMPRO tool. Qual Life Res. 2016;25(10):2467–80.PubMedCrossRef
11.
go back to reference Weinstein MC, Torrance G, Mcguire A. QALYs: the basics. Value Health. 2009;12(s1):5–9.CrossRef Weinstein MC, Torrance G, Mcguire A. QALYs: the basics. Value Health. 2009;12(s1):5–9.CrossRef
13.
15.
go back to reference Zhu J, Wang L, He SJ, Huang HY, Li J, Yan SP, Fang Y, Dai M, Shi JF. Health utility score of breast cancer in China: a systematic review. Chin J Evidence-based Med. 2017;17(9):1066–71 Chinese. Zhu J, Wang L, He SJ, Huang HY, Li J, Yan SP, Fang Y, Dai M, Shi JF. Health utility score of breast cancer in China: a systematic review. Chin J Evidence-based Med. 2017;17(9):1066–71 Chinese.
16.
go back to reference Dakin H, Abel L, Burns R, Yang Y. Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement. Health Qual Life Outcomes. 2018;16(1):31.PubMedPubMedCentralCrossRef Dakin H, Abel L, Burns R, Yang Y. Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement. Health Qual Life Outcomes. 2018;16(1):31.PubMedPubMedCentralCrossRef
17.
go back to reference Cheung YB, Luo N, Ng R, Lee CF. Mapping the functional assessment of cancer therapy-breast (FACT-B) to the 5-level EuroQoL Group’s 5-dimension questionnaire (EQ-5D-5L) utility index in a multi-ethnic Asian population. Health Qual Life Outcomes. 2014;12(1):180.PubMedPubMedCentralCrossRef Cheung YB, Luo N, Ng R, Lee CF. Mapping the functional assessment of cancer therapy-breast (FACT-B) to the 5-level EuroQoL Group’s 5-dimension questionnaire (EQ-5D-5L) utility index in a multi-ethnic Asian population. Health Qual Life Outcomes. 2014;12(1):180.PubMedPubMedCentralCrossRef
18.
go back to reference Lee CF, Ng R, Luo N, Cheung YB. Development of conversion functions mapping the FACT-B total score to the EQ-5D-5L utility value by three linking methods and comparison with the ordinary least square method. Appl Health Econ Health Policy. 2018;16(5):685–95.PubMedCrossRef Lee CF, Ng R, Luo N, Cheung YB. Development of conversion functions mapping the FACT-B total score to the EQ-5D-5L utility value by three linking methods and comparison with the ordinary least square method. Appl Health Econ Health Policy. 2018;16(5):685–95.PubMedCrossRef
19.
go back to reference Gray LA, Wailoo AJ, Hernandez AM. Mapping the FACT-B instrument to EQ-5D-3L in patients with breast cancer using adjusted limited dependent variable mixture models versus response mapping. Value Health. 2018;21(12):1399–405.PubMedPubMedCentralCrossRef Gray LA, Wailoo AJ, Hernandez AM. Mapping the FACT-B instrument to EQ-5D-3L in patients with breast cancer using adjusted limited dependent variable mixture models versus response mapping. Value Health. 2018;21(12):1399–405.PubMedPubMedCentralCrossRef
20.
go back to reference Norman R, Cronin P, Viney R, King M, Street D, Ratcliffe J. International comparisons in valuing EQ-5D health states: a review and analysis. Value Health. 2009;12(8):1194–200.PubMedCrossRef Norman R, Cronin P, Viney R, King M, Street D, Ratcliffe J. International comparisons in valuing EQ-5D health states: a review and analysis. Value Health. 2009;12(8):1194–200.PubMedCrossRef
21.
go back to reference Trogdon JG, Ekwueme DU, Chamiec-Case L, Guy GP Jr. Breast cancer in young women: health state utility impacts by race/ethnicity. Am J Prev Med. 2016;50(2):262–9.PubMedPubMedCentralCrossRef Trogdon JG, Ekwueme DU, Chamiec-Case L, Guy GP Jr. Breast cancer in young women: health state utility impacts by race/ethnicity. Am J Prev Med. 2016;50(2):262–9.PubMedPubMedCentralCrossRef
22.
go back to reference Knuttel FM, van den Bosch MA, Young-Afat DA, Emaus MJ, van den Bongard DH, Witkamp AJ, Verkooijen HM. Patient preferences for minimally invasive and open locoregional treatment for early-stage breast cancer. Value Health. 2017;20(3):474–80.PubMedCrossRef Knuttel FM, van den Bosch MA, Young-Afat DA, Emaus MJ, van den Bongard DH, Witkamp AJ, Verkooijen HM. Patient preferences for minimally invasive and open locoregional treatment for early-stage breast cancer. Value Health. 2017;20(3):474–80.PubMedCrossRef
23.
go back to reference Shih V, Chan A, Xie F, Ko Y. Health state utility assessment for breast cancer. Value Health Reg Issues. 2012;1(1):93–7.PubMedCrossRef Shih V, Chan A, Xie F, Ko Y. Health state utility assessment for breast cancer. Value Health Reg Issues. 2012;1(1):93–7.PubMedCrossRef
24.
go back to reference Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G. Reliability and validity of the functional assessment of Cancer therapy-breast quality-of-life instrument. J Clin Oncol. 1997;15(3):974–86.PubMedCrossRef Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G. Reliability and validity of the functional assessment of Cancer therapy-breast quality-of-life instrument. J Clin Oncol. 1997;15(3):974–86.PubMedCrossRef
25.
go back to reference Wan CH, Zhang DM, Tang XL, Zhang WL, Li WH, Ren HX, He RS, Wang W. Revision of the Chinese version of the FACT-B for patients with breast cancer. Chin Mental Health J. 2003;17(5):298–300 Chinese. Wan CH, Zhang DM, Tang XL, Zhang WL, Li WH, Ren HX, He RS, Wang W. Revision of the Chinese version of the FACT-B for patients with breast cancer. Chin Mental Health J. 2003;17(5):298–300 Chinese.
26.
go back to reference Xin YB, Ma AX. Study on reliability and validity of Chinese version of EQ-5D-5L. Shanghai Med Pharmaceutical J. 2013;34(9):40–3 Chinese. Xin YB, Ma AX. Study on reliability and validity of Chinese version of EQ-5D-5L. Shanghai Med Pharmaceutical J. 2013;34(9):40–3 Chinese.
27.
go back to reference Luo N, Liu G, Li M, Guan H, Jin X, Rand-Hendriksen K. Estimating an EQ-5D-5L value set for China. Value Health. 2017;20(4):662–9.PubMedCrossRef Luo N, Liu G, Li M, Guan H, Jin X, Rand-Hendriksen K. Estimating an EQ-5D-5L value set for China. Value Health. 2017;20(4):662–9.PubMedCrossRef
28.
go back to reference Brazier JE, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010;11(2):215–25.PubMedCrossRef Brazier JE, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010;11(2):215–25.PubMedCrossRef
29.
go back to reference Kim SH, Kim SO, Lee S, Jo MW. Deriving a mapping algorithm for converting SF-36 scores to EQ-5D utility score in a Korean population. Health Qual Life Outcomes. 2014;12(1):145.PubMedPubMedCentralCrossRef Kim SH, Kim SO, Lee S, Jo MW. Deriving a mapping algorithm for converting SF-36 scores to EQ-5D utility score in a Korean population. Health Qual Life Outcomes. 2014;12(1):145.PubMedPubMedCentralCrossRef
30.
31.
go back to reference Longworth L, Rowen D. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health. 2013;16(1):202–10.PubMedCrossRef Longworth L, Rowen D. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health. 2013;16(1):202–10.PubMedCrossRef
32.
go back to reference Dow WH, Norton EC. Choosing between and interpreting the Heckit and two-part models for corner solutions. Health Serv Outcome Res Methodol. 2003;4(1):5–18.CrossRef Dow WH, Norton EC. Choosing between and interpreting the Heckit and two-part models for corner solutions. Health Serv Outcome Res Methodol. 2003;4(1):5–18.CrossRef
33.
go back to reference Acaster S, Pinder B, Mukuria C, Copans A. Mapping the EQ-5D index from the cystic fibrosis questionnaire-revised using multiple modelling approaches. Health Qual Life Outcomes. 2015;13(1):33.PubMedPubMedCentralCrossRef Acaster S, Pinder B, Mukuria C, Copans A. Mapping the EQ-5D index from the cystic fibrosis questionnaire-revised using multiple modelling approaches. Health Qual Life Outcomes. 2015;13(1):33.PubMedPubMedCentralCrossRef
34.
go back to reference Dakin H, Gray A, Murray D. Mapping analyses to estimate EQ-5D utilities and responses based on Oxford knee score. Qual Life Res. 2013;22(3):683–94.PubMedCrossRef Dakin H, Gray A, Murray D. Mapping analyses to estimate EQ-5D utilities and responses based on Oxford knee score. Qual Life Res. 2013;22(3):683–94.PubMedCrossRef
35.
36.
go back to reference Young TA, Mukuria C, Rowen D, Brazier JE, Longworth L. Mapping functions in health-related quality of life: mapping from two cancer-specific health-related quality-of-life instruments to EQ-5D-3L. Med Decis Mak. 2015;35(7):912–26.CrossRef Young TA, Mukuria C, Rowen D, Brazier JE, Longworth L. Mapping functions in health-related quality of life: mapping from two cancer-specific health-related quality-of-life instruments to EQ-5D-3L. Med Decis Mak. 2015;35(7):912–26.CrossRef
37.
go back to reference McDonough CM, Grove MR, Elledge AD, Tosteson AN. Predicting EQ-5D-US and SF-6D societal health state values from the osteoporosis assessment questionnaire. Osteoporos Int. 2012;23(2):723–32.PubMedCrossRef McDonough CM, Grove MR, Elledge AD, Tosteson AN. Predicting EQ-5D-US and SF-6D societal health state values from the osteoporosis assessment questionnaire. Osteoporos Int. 2012;23(2):723–32.PubMedCrossRef
38.
go back to reference Ali FM, Kay R, Finlay AY, Piguet V, Kupfer J, Dalgard F, Salek MS. Mapping of the DLQI scores to EQ-5D utility values using ordinal logistic regression. Qual Life Res. 2017;26(11):3025–34.PubMedPubMedCentralCrossRef Ali FM, Kay R, Finlay AY, Piguet V, Kupfer J, Dalgard F, Salek MS. Mapping of the DLQI scores to EQ-5D utility values using ordinal logistic regression. Qual Life Res. 2017;26(11):3025–34.PubMedPubMedCentralCrossRef
39.
go back to reference Cheung YB, Thumboo J, Gao F, Ng GY, Pang G, Koo WH, Sethi VK, Wee J, Goh C. Mapping the English and Chinese versions of the functional assessment of Cancer therapy-general to the EQ-5D utility index. Value Health. 2009;12(2):371–6.PubMedCrossRef Cheung YB, Thumboo J, Gao F, Ng GY, Pang G, Koo WH, Sethi VK, Wee J, Goh C. Mapping the English and Chinese versions of the functional assessment of Cancer therapy-general to the EQ-5D utility index. Value Health. 2009;12(2):371–6.PubMedCrossRef
40.
go back to reference Wu EQ, Mulani P, Farrell MH, Sleep D. Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients. Value Health. 2007;10(5):408–14.PubMedCrossRef Wu EQ, Mulani P, Farrell MH, Sleep D. Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients. Value Health. 2007;10(5):408–14.PubMedCrossRef
41.
go back to reference Crott R, Briggs A. Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. Eur J Health Econ. 2010;11(4):427–34.PubMedCrossRef Crott R, Briggs A. Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. Eur J Health Econ. 2010;11(4):427–34.PubMedCrossRef
42.
43.
go back to reference Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health. 2008;11(7):1131–43.PubMedCrossRef Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health. 2008;11(7):1131–43.PubMedCrossRef
45.
go back to reference Hays RD, Revicki DA, Feeny D, et al. Using linear equating to map PROMIS global health items and the PROMIS-29 V. 2 profile measure to the health utilities index—mark 3. Pharmacoeconomics. 2016;34(10):1015–22.PubMedPubMedCentralCrossRef Hays RD, Revicki DA, Feeny D, et al. Using linear equating to map PROMIS global health items and the PROMIS-29 V. 2 profile measure to the health utilities index—mark 3. Pharmacoeconomics. 2016;34(10):1015–22.PubMedPubMedCentralCrossRef
Metadata
Title
Mapping function from FACT-B to EQ-5D-5 L using multiple modelling approaches: data from breast cancer patients in China
Authors
Qing Yang
Xue Xin Yu
Wei Zhang
Hui Li
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2019
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-019-1224-8

Other articles of this Issue 1/2019

Health and Quality of Life Outcomes 1/2019 Go to the issue